ETV6 Antibody

1. In this study, the presence of clonal heterogeneity and impaired FCM-MRD clearance among ETV6/RUNX1-positive patients, ultimately influenced prognosis. PMID: 29778230
2. In the Title. PMID: 29064485
3. s have shown that the stability of ETV6/FLT3 is regulated by the Hsp90 chaperone. ETV6/FLT3 fusion protein forms a complex with Hsp90 by coimmunoprecipitation analyses using an Hsp90 antibody. PMID: 29471895
4. None of the genitourinary pseudosarcomatous myofibroblastic proliferations was found to harbour USP6 (0/12), ROS1 (0/8) or ETV6 (0/7) rearrangements PMID: 29617048
5. ETV6 rearrangements often accompany other molecular mutations. Thirty-three distinct partner bands of ETV6 that contain various fusion genes were detected which plays a vital role in obtaining information about leukaemia genesis. RXDX-101 and PKC412 were reported to be inhibitors of ETV6-NTRK3. PMID: 29894279
6. We did not find the AIF1L-ETV6 and ABL1-AIF1L fusions in other ETV6-ABL1-positive ALL. Nevertheless, functional studies would be needed to establish the biological role of AIF1L-ETV6 and ABL1-AIF1L and to determine whether they contribute to leukemogenesis and/or to the final leukemia phenotype. PMID: 29726059
7. Data indicate that single nucleotide polymorphism rs2238126 in ETS variant 6 transcription factor (ETV6) associated with colorectal cancer risk. PMID: 27145994
8. ETV6/NTRK3 fusion oncogene is associated with papillary thyroid carcinoma. PMID: 29427554
9. Nasopharyngeal carcinoma (NPC) super-enhancers with extraordinarily broad and high H3K27ac signals were identified, and they were linked to genes important for oncogenesis including ETV6. ETV6 was also highly expressed in NPC biopsies by immunohistochemistry PMID: 28831010
10. ETV6-RUNX1 mutation is associated with childhood acute B-lymphoblastic leukemia. PMID: 29290585
11. Several studies addressed the mechanism by which ETV6/RUNX1 (E/R) contributes to leukemogenesis, including the necessary secondary genetic lesions, the cellular framework in which E/R initially arises and the maintenance of a pre-leukemic condition. [review] PMID: 28418909
12. Patients with t(12;22)/MN1-EVT6 oncogene, are frequently associated with myeloid neoplasms, poor response to chemotherapy, and inferior outcome. PMID: 29273914
13. Presence of fusion the genes BCR/ABL1, ETV6/RUNX1, and MLL/AF4 does not have any impact on the clinical and laboratory features of ALL at presentation. PMID: 26856288
14. ETV6/RUNX1 (+) ALL may be heterogeneous in terms of prognosis, and variables such as MRD at end ofremission induction or additional structural abnormalities of 12p could define a subset of patients who are likely to have poor outcome. PMID: 27506214
15. Case Reports: mammary analog secretory carcinoma of the thyroid gland with ETV6 rearrangement and ETV6-NTRK3 gene fusion. PMID: 27282352
16. The prevalence of ETV6-NTRK3 kinase fusions were determined in papillary thyroid cancer ofan adult population PMID: 29046324
17. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as Mammary analogue secretory carcinoma after next-generation sequencing revealed an ETV6-NTRK3 fusion. PMID: 26884591
18. Letter/Case Report: ETV6/MECOM gene fusion in therapy-related acute myeloid leukemia with t(3;12) and monosomy 7. PMID: 28182364
19. ETV6-LYN leukemic fusion transcript due to chromosomes 1, 8 and 12 rearrangement is associated with acute myeloid leukemia. PMID: 29153093
20. Report ETV6-rearranged low-grade sinonasal adenocarcinomas. PMID: 28719468
21. will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome[review] PMID: 28555414
22. The clinical significance of ETV6-RUNX1. PMID: 28299659
23. Deliver the necessary promotional drive for the progression of ETV6-RUNX1+ pre-leukaemic cells. PMID: 28299660
24. Data suggest that, for ETV6 (which harbors only a single DNA contact interface for both specific and nonspecific interactions), intersegmental jumping represents a major molecular event that significantly modifies the thermodynamics and kinetics of DNA target search; site-specific DNA binding by ETV6 involves a kinetic intermediate at the cognate sequence. PMID: 28592487
25. Our findings suggest ETV6-RUNX1 is associated with space-time clustering of childhood leukemia (CL) and are consistent with an infection interacting with that oncogene in early life leading to clinical leukemia. PMID: 28129329
26. EGFR activation leads to the induction of miR-96 expression and suppression of ETV6, which contributes to prostate cancer progression. PMID: 27746161
27. we demonstrate the expression of the ETV6-NTRK3 fusion oncogene in a small subset of inflammatory myofibroblastic tumors PMID: 27259007
28. ETV6-NTRK3 translocated papillary thyroid carcinomas are locoregionally aggressive and can metastasize distantly. PMID: 28125451
29. We report 6 cases of secretory carcinomas of the skin harboring the ETV6-NTRK3 gene fusion PMID: 27631515
30. ETV6-ABL1 fusion occurs in both lymphoid and myeloid leukemias; the genomic profile and clinical behavior resemble BCR-ABL1-positive malignancies, including the unfavorable prognosis, particularly of acute leukemias. The poor outcome suggests that treatment with tyrosine kinase inhibitors should be considered for patients with this fusion. PMID: 27229714
31. ETV6-NTRK3, MYO5A-NTRK3 and MYH9-NTRK3 fusions are identified in Spitz tumours and demonstrated that NTRK3 fusions constitutively activate the mitogen-activated protein kinase, phosphoinositide 3-kinase and phospholipase Cgamma1 pathways in melanocytes. PMID: 27477320
32. A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism. PMID: 26647767
33. loss of ETV6 leads to significant overexpression of CLIC5, which in turn leads to decreased lysosome-mediated apoptosis. Our data suggest that heightened CLIC5 activity could promote a permissive environment for oxidative stress-induced DNA damage accumulation, and thereby contribute to leukemogenesis. PMID: 27540136
34. the effects of various aberrations in ETV6 and RUNX1 gene copy number on disease prognosis were evaluated in 21 pediatric patients diagnosed with B-cell ALL with/without t(12;21). PMID: 27393278
35. Case Report: ETV6-NTRK3 translocation in primary cutaneous mammary analog secretory carcinoma. PMID: 27763904
36. ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. PMID: 26852652
37. The study shows a low representation of ETV6-RUNX1 fusion oncogenes among pediatric acute lymphoblastic leukemia patients from King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia. PMID: 26625756
38. the ETV6-NTRK3 fusion might identify a subset of gastrointestinal stromal tumours with peculiar clinicopathological characteristics PMID: 26606880
39. our results demonstrate that MIR181A1 and ETV6/RUNX1 regulate each other, and we propose that a double negative loop involving MIR181A1 and ETV6/RUNX1 may contribute to ETV6/RUNX1-driven arrest of differentiation in pre-B ALL. PMID: 26580398
40. germline ETV6 mutations associated with leukemia and thrombocytopenia were identifies in multiple individuals. Mutant ETV6 showed decreased ability to regulate expression of other genes. PMID: 26102509
41. We observed significant enrichment of the neuroactive ligand-receptor interaction pathway in TCF3-PBX1 as well as an enrichment of genes involved in immunity and infection pathways in ETV6-RUNX1 subtype PMID: 26237075
42. Our study demonstrated that ETV6 was markedly involved in the development of non-small cell lung cancer and could serve as a potential prognostic marker for this deadly disease PMID: 26045802
43. Suggest germline ETV6 variations as the basis of a novel genetic syndrome associated with predisposition to childhood acute lymphoblastic leukemia. PMID: 26522332
44. Molecular analysis of ETV6 gene rearranged mammary analogue secretory carcinoma of salivary glands tumors with lack of classical ETV6-NTRK3 fusion. PMID: 26492182
45. the ETV6/ARG oncoprotein contributes to autonomous cell growth by compensating for the requirement of growth factor through activating STAT5 signaling, which leads to the up-regulation of c-Myc. PMID: 25373509
46. TEL-AML1 fusion protein blocks B-cell differentiation and downregulates the IRF3-IFNalpha/beta pathway by modulating expression and phosphorylation of IRF3 in human primary hematopoietic precursor cells. PMID: 25893288
47. Spectrum of secretory breast carcinoma with ETV6-NTRK3 gene fusion ranging from low-grade to high-grade histology, with occasional low hormonal receptor expression, simplex genomic profiles, and possible unfavorable course. PMID: 26291510
48. A key role for ETV6 in platelet formation and leukemia predisposition. PMID: 25807284
49. Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumour that harbours the recurrent ETV6-NTRK3 translocation. PMID: 25503077
50. frequency and spectrum of somatic mutations of ETV6 in hematologic malignancies; findings suggest somatic mutations of ETV6 are infrequent but recurrent in a wider range of myeloid or lymphoid malignancies, including MDS, AML, ETP-ALL, CLL, MPAL, B-ALL and CML PMID: 24997145

显示更多

收起更多

HGNC: 3495

OMIM: 131440

KEGG: hsa:2120

STRING: 9606.ENSP00000379658

UniGene: Hs.504765